Narkolepsi og andre hypersomnier

Tidsskrift for den Norske Laegeforening

Volumn 129, Issue 19, 2009, Pages 2007-2010

  Sand, Trond ^a,b   Schrader, Harald ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; CHILD; DIFFERENTIAL DIAGNOSIS; HUMAN; NARCOLEPSY; PROGNOSIS; PSYCHOLOGICAL ASPECT; REVIEW; SOMNOLENCE;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DIAGNOSIS, DIFFERENTIAL; DISORDERS OF EXCESSIVE SOMNOLENCE; HUMANS; NARCOLEPSY; PROGNOSIS; SEROTONIN UPTAKE INHIBITORS;

EID: 70350488908     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.08.0655     Document Type: Article

References (22)

1. Guilleminault G, Fromherz S. Narcolepsy: diagnosis and management. I: Kruger MH, Roth J, Dement WC, red. Principles and practice in sleep medicine. 4. utg. Philadelphia, PA: Saunders, 2005: 780-90.
2. Mignot E. Narcolepsy: pharmacology, pathophysiology, and genetics. I: Kruger MH, Roth J, Dement WC, red. Principles and practice in sleep medicine. 4. utg. Philadelphia, PA: Saunders, 2005: 761-79.
3. Bjorvatn B, Akre H, Skard Heier M et al. Utredning og behandling av søvnrelaterte sykdommer. Oslo: Statens helsetilsyn, 2001.
4. International classification of sleep disorders. 2. utg. Westchester, IL: American Academy of Sleep Medicine, 2005.
5. Billiard M. Diagnosis of narcolepsy and idiopathic hypersomnia: an update based on the international classification of sleep disorders, 2nd edition. Sleep Med Rev 2007; 11: 377-88.
6. Gautvik KM, de Lecea L, Gautvik VT et al. Overview of the most prevalent hypothalamus-specific mRNAs, as identified by directional tag PCR subtraction. Proc Natl Acad Sci USA 1996; 93: 8733-8.
7. Fronczek R, Baumann CR, Lammers GJ et al. Hypocretin/orexin disturbances in neurological disorders. Sleep Med Rev 2009; 13: 9-22.
8. Heier MS, Evsiukova T, Vilming S et al. CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway. Sleep 2007; 30: 969-73.
9. Overeem S, Black JL, Lammers GJ. Narcolepsy: immunological aspects. Sleep Med Rev 2008; 12: 95-107.
10. Silber MH. Narcolepsy, head injury, and the problem of causality. J Clin Sleep Med 2005; 1: 157-8.
11. Sand T. Søvnlidelser må utredes før behandling. Tidsskr Nor Lægeforen 2004; 124: 2877.
12. Johns MW. Sleepiness in different situations measured by the Epworth Sleepiness Scale. Sleep 1994; 17: 703-10.
13. Arand D, Bonnet M, Hurwitz T et al. The clinical use of the MSLT and MWT. Sleep 2005; 28: 123-44.
14. Sand T, red. Retningslinjer for metoder i klinisk nevrofysiologi del 1. 2. utg. Oslo: Den norske legeforening, 2008.
15. Singh M, Drake CL, Roth T. The prevalence of multiple sleep-onset REM periods in a population-based sample. Sleep 2006; 29: 890-5.
16. Aldrich MS, Chervin RD, Malow BA. Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy. Sleep 1997; 20: 620-9.
17. Morgenthaler TI, Kapur VK, Brown T et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007; 30: 1705-11.
18. Volkow ND, Fowler JS, Logan J et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain. JAMA 2009; 301: 1148-54.
19. Schrader H. Behandling av aksessoriske symptomer ved narkolepsi med anafranil. Tidsskr Nor Lægeforen 1981; 101: 1201-3.
20. Schrader H, Kayed K, Bendixen Markset AC et al. The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo Acta Neurol Scand 1986; 74: 297-303.
21. Billiard M, Bassetti C, Dauvilliers Y et al. EFNS guidelines on management of narcolepsy. Eur J Neurol 2006; 13: 1035-48.
22. Billiard M, Dauvilliers Y. Idiopathic hypersomnia. Sleep Med Rev 2001; 5: 351-60.